



**QUEEN'S  
UNIVERSITY  
BELFAST**

## **Geographic Differences in Baseline Prostate Inflammation and Relationship with Subsequent Prostate Cancer Risk: Results from the Multinational REDUCE Trial**

Allott, E. H., Markt, S. C., Howard, L. E., Vidal, A. C., Moreira, D. M., Castro-Santamaria, R., Andriole, G. L., Mucci, L. A., & Freedland, S. J. (2018). Geographic Differences in Baseline Prostate Inflammation and Relationship with Subsequent Prostate Cancer Risk: Results from the Multinational REDUCE Trial. *Cancer Epidemiology Biomarkers & Prevention*, 27(7), 783-789. <https://doi.org/10.1158/1055-9965.EPI-18-0076>

**Published in:**  
Cancer Epidemiology Biomarkers & Prevention

**Document Version:**  
Peer reviewed version

**Queen's University Belfast - Research Portal:**  
[Link to publication record in Queen's University Belfast Research Portal](#)

### **Publisher rights**

© 2018 American Association for Cancer Research.  
This work is made available online in accordance with the publisher's policies. Please refer to any applicable terms of use of the publisher.

### **General rights**

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

### **Take down policy**

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact [openaccess@qub.ac.uk](mailto:openaccess@qub.ac.uk).

### **Open Access**

This research has been made openly available by Queen's academics and its Open Research team. We would love to hear how access to this research benefits you. – Share your feedback with us: <http://go.qub.ac.uk/oa-feedback>

**Geographic differences in baseline prostate inflammation and relationship with subsequent prostate cancer risk: results from the multinational REDUCE trial**

Emma H. Allott<sup>1,2,3</sup>, Sarah C. Markt<sup>3</sup>, Lauren E. Howard<sup>4</sup>, Adriana C. Vidal<sup>5</sup>, Daniel M. Moreira<sup>6</sup>, Ramiro Castro-Santamaria<sup>7</sup>, Gerald L. Andriole<sup>8</sup>, Lorelei A. Mucci<sup>3</sup>, Stephen J. Freedland<sup>5,9</sup>

<sup>1</sup>Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC

<sup>2</sup>Department of Histopathology and Morbid Anatomy, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland

<sup>3</sup>Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, MA

<sup>4</sup>Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC

<sup>5</sup>Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA

<sup>6</sup>Department of Urology, University of Illinois at Chicago, Chicago, IL

<sup>7</sup>Research and Development, GlaxoSmithKline, Inc., King of Prussia, PA

<sup>8</sup>Washington University School of Medicine in St. Louis, St. Louis, MO

<sup>9</sup>Division of Urology, Veterans Affairs Medical Center, Durham, NC

**Running title:** Global differences in prostate inflammation and cancer risk

**Abbreviations:** BMI, body mass index; CPSI, chronic prostatitis symptom index; DRE, digital rectal exam; H&E, hematoxylin and eosin; IPSS, International Prostate Symptom Score; NSAID, non-steroidal anti-inflammatory drug; PCPT, Prostate Cancer Prevention Trial; PSA, prostate cancer-specific antigen; REDUCE, Reduction by Dutasteride of Prostate Cancer Events; TRUS, transrectal ultrasound

**Corresponding author:** Dr. Emma H. Allott, Department of Nutrition, CB 7461, University of North Carolina at Chapel Hill, 135 Dauer Drive, Chapel Hill, NC 27599, USA. Phone: +1 919-966-7230; Fax: +1 919-966-2089; E-mail: [allott@email.unc.edu](mailto:allott@email.unc.edu)

**Conflicts of interest:** The REDUCE study was funded by GlaxoSmithKline. Ramiro Castro-Santamaria is an employee of GlaxoSmithKline. Dr Andriole is a consultant for GlaxoSmithKline.

**Word count:** 250 (abstract), 3,403 (text)

## **Abstract**

**Background:** Prostate cancer (PC) incidence rates vary 25-fold worldwide. Differences in PSA screening are largely, but not entirely, responsible. We examined geographic differences in prevalence of histologic prostate inflammation and subsequent PC risk.

**Methods:** 7,000 non-Hispanic white men were enrolled in the REDUCE trial from Europe (n=4,644), North America (n=1,746), South America (n=466), and Australia/New Zealand (n=144). Histologic inflammation in baseline negative prostate biopsies was classified as chronic (lymphocytes/macrophages) or acute (neutrophils). Multivariable logistic regression was used to examine associations between region and prostate inflammation, and between region and PC risk at 2-year biopsy.

**Results:** Prevalence of prostate inflammation varied across region, with broadly similar patterns for acute and chronic inflammation. Relative to Europe, prevalence of acute inflammation was higher in North America (OR 1.77; 95%CI 1.51-2.08) and Australia/New Zealand (OR 2.07; 95%CI 1.40-3.06). Men from these regions had lower PC risk than Europeans at biopsy. Among North Americans, prevalence of acute inflammation was higher in Canada versus the US (OR 1.40; 95%CI 1.07-1.83), but PC risk did not differ between these regions. Among Europeans, prevalence of acute inflammation was lower in Northern and Eastern (OR 0.79; 95%CI 0.65-0.97 and OR 0.62; 95%CI 0.45-0.87, respectively), relative to Western Europe, and these men had higher PC risk at biopsy.

**Conclusions:** Prevalence of histologic prostate inflammation varied by region. Geographic differences in prostate inflammation tracked inversely with geographic differences in PC risk.

**Impact:** Characterization of premalignant prostate biology and the relationship with subsequent prostate cancer risk could inform prostate cancer prevention efforts.

## Introduction

Prostate cancer incidence rates vary more than 25-fold worldwide, and are highest in higher-resource countries [1]. While much of this variation can be explained by differences in prostate-specific antigen (PSA) screening, geographic variation in incidence rates was noted prior to the PSA screening era. Therefore, lifestyle factors associated with high-resource areas, including Westernized diet, physical inactivity and obesity, may contribute to geographic variation in prostate cancer incidence rates [2]. Identifying mechanisms contributing to geographic variation in incidence rates could inform prostate cancer prevention efforts.

Histologic evaluation of negative biopsies has revealed prostate inflammation in 60-80% of asymptomatic men undergoing a biopsy due to elevated PSA [3-6]. Causes are not well understood, but a case-control study nested within the Prostate Cancer Prevention Trial (PCPT) reported that serum omega-3 and omega-6 fatty acid levels were associated with histologic prostate inflammation [3]. Using data from the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial, we reported that current smokers were more likely to have histologic prostate inflammation than non-smokers [7], while statin users were less likely to have histologic prostate inflammation than non-users [8]. Together, these studies suggest that lifestyle factors influence histologic prostate inflammation which, in turn, may affect prostate cancer risk [9].

Herein, using data from the multinational REDUCE trial, we examined geographic differences in the prevalence of histologic inflammation in negative baseline prostate biopsies, and the relationship with prostate cancer risk at trial-mandated repeat biopsy. We hypothesized that the prevalence of histologic prostate inflammation would vary by geographic region. Further, given an etiologic role for inflammation in prostate cancer [9], we hypothesized that geographic

differences in the prevalence of histologic prostate inflammation would be accompanied by geographic differences in prostate cancer risk.

## **Materials and Methods**

### *Study population*

REDUCE was a four year double-blind and placebo-controlled trial [10]. Eligible men were 50-75 years of age, with a serum PSA of 2.5-10 ng/ml (if  $\leq 60$ ) or 3-10 ng/ml (if  $>60$ ), and a single, negative biopsy (6-12 cores) within 6 months before enrollment (independent of trial). Baseline biopsies were centrally reviewed to confirm a negative prostate cancer diagnosis. Men were ineligible if they had more than one negative biopsy, a history of prostate cancer, high-grade prostatic intraepithelial neoplasia, atypical small acinar proliferation, a prostate volume  $>80$  ml, had undergone previous prostate surgery, or had an International Prostate Symptom Score (IPSS)  $\geq 25$  or  $\geq 20$  while receiving  $\alpha$ -blockers for treatment of benign prostatic hyperplasia. The REDUCE protocol was approved by the Institutional Review Boards at each site, and all participants provided written informed consent.

### *Data collection and variable definitions*

At baseline, a detailed medical history was obtained including body mass index (BMI), smoking and alcohol use, medical comorbidities, and medication use. Prostate volume was measured by ultrasonography at the time of the baseline negative biopsy.

Histologic prostate inflammation was assessed by central review of baseline negative prostate biopsies stained with hematoxylin and eosin (H&E) by a single pathologist blinded to clinical

data, using a standardized published method [11]. Chronic histologic inflammation consisted mainly of lymphocytes and variable number of plasma cells and macrophages. Acute histologic inflammation consisted of neutrophils. Our primary analysis examined presence of any inflammation vs. absence of inflammation, for chronic and acute inflammation separately. We also examined extent of chronic and acute inflammation, categorized as none, moderate ( $>0\%$  -  $<20\%$ ), and severe ( $\geq 20\%$  of biopsy cores), as previously described [8]. In sensitivity analysis, we examined the extent of chronic and acute inflammation within individual biopsy cores, categorized as none, mild, moderate, and marked, as previously described [11].

Transrectal ultrasound (TRUS)-guided 10-core biopsies were performed at 2 years and 4 years post-randomization using trial-specified protocols, and were evaluated for prostate cancer by the central pathology facility.

Geographic region was categorized as Europe, North America, South America and Australia/New Zealand. Europe was further subdivided into Western (France, Germany, Belgium, Netherlands, Switzerland, Austria), Northern (Ireland, United Kingdom, Norway, Sweden, Finland, Denmark, Latvia, Lithuania, Estonia), Southern (Italy, Spain, Portugal, Slovenia, Croatia, Greece), and Eastern (Bulgaria, Belarus, Hungary, Poland, Romania, Russia, Slovakia, Ukraine) regions, according the United Nations Statistics Division (<http://unstats.un.org/unsd/methods/m49/m49regin.htm>). North America was subdivided into the United States (US) and Canada. Regions within South America (Argentina, Brazil, Chile) contained too few participants for subdivision.

### *Statistical analysis*



A total of 8,122 men were enrolled in the efficacy population of REDUCE. We excluded men with a baseline PSA outside the trial eligibility range (n=112). Given that the prevalence of prostate inflammation varies by race/ethnicity [12, 13] and race/ethnicity varies by geographic region, we excluded non-white and Hispanic men (n=713) to minimize this potential source of confounding. We also excluded men from Africa given the low number of white participants in this region (n=84). Finally, we excluded men with missing data for covariates, including smoking (n=5), BMI (n=109), digital rectal exam (DRE) findings (n=9), family history of prostate cancer (n=5) and prostate volume (n=85), resulting in n=7,000 men in the present analysis.

Logistic regression was used to generate age-adjusted and multivariable-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) to examine geographic differences in the prevalence of acute and chronic histologic inflammation (presence vs. absence, for each type of inflammation separately) in baseline negative prostate biopsies. In secondary analysis, we used multinomial logistic regression to examine geographic differences in the prevalence of chronic inflammation only, acute inflammation only, and both types of inflammation, treating men with neither type of inflammation as the reference group. We also examined geographic differences in the extent of acute and chronic histologic inflammation (classified as <20% and  $\geq$ 20% vs. 0% of cores, and as mild or moderate/marked vs. none, for each type of inflammation separately) using multinomial logistic regression. Multivariable models were adjusted for baseline characteristics, including age (continuous), BMI (continuous), statin use (no, yes), non-steroidal anti-inflammatory drug (NSAID) use (no, yes), smoking status (never, former, current), family history of prostate cancer (no, yes), DRE findings (abnormal, normal/enlarged), prostate volume (grams; continuous), and PSA (ng/ml; continuous). We further adjusted for IPSS in sensitivity

analysis but this did not substantially change our results and so these findings are not presented. We did not adjust models for chronic prostatitis symptom index (CPSI) as this was previously shown to be unrelated to prostate inflammation in REDUCE [14]. We stratified analyses of associations between geographic region and prostate inflammation by baseline PSA ( $\geq$ median vs.  $<$ median), smoking status (current vs. never/former), NSAID (yes vs. no) and statin use (yes vs. no) to test each of these factors as potential effect modifiers of the association between geographic region and prostate inflammation. We stratified analyses of associations between regions and prostate cancer risk by family history of prostate cancer (yes vs. no), obesity status (BMI  $\geq$ 30 vs.  $<$ 30 kg/m<sup>2</sup>), NSAID and statin use. We tested for interaction between each of these factors and geographic region for in association with prostate inflammation or prostate cancer risk by incorporating a cross product term into the logistic regression model, and testing its significance using the Wald test. We explored geographic differences in prostate inflammation at the 2-year biopsy using the same approach as described for baseline biopsies, with models additionally adjusted for treatment arm.

We also used logistic regression to examine differences in prostate cancer risk at trial-mandated 2-year repeat biopsy across geographic regions. These multivariable models were adjusted for the aforementioned covariates in addition to treatment arm (placebo, dutasteride). In sensitivity analysis, we explored further adjusting prostate cancer risk models for acute and chronic histologic prostate inflammation, and we also performed analyses stratified by treatment arm. We had a reduced sample size with which to examine geographic differences in prostate cancer risk at 4-year repeat biopsy and, given that findings were similar to those at 2-year repeat biopsy, they are not presented. We did not examine geographic differences in prostate cancer risk stratified by Gleason grade given low numbers of high-grade prostate cancers.

Statistical analysis was performed using Stata, version 13.0 (Stata Corp., College Station, TX, USA).

## **Results**

### *Baseline characteristics of REDUCE participants by geographic region*

Of 7,000 men, Europeans formed the majority (66%), followed by North Americans (25%), South Americans (7%) and Australian/New Zealanders (2%). There were slight differences in age and PSA by region (Table 1). North Americans and Australian/New Zealanders were more likely to have an abnormal DRE than Europeans and South Americans (8% and 6% vs. 2% and 1%, respectively). Relative to other regions, North Americans were more likely to have a family history of prostate cancer (23% vs. 10% in Europe, 11% in South America, and 15% in Australia/New Zealand).

The prevalence of obesity, defined as BMI  $\geq 30$  kg/m<sup>2</sup>, was highest in North America (28%), followed by Australia/New Zealand (24%), South America (20%) and Europe (18%; Table 1). Prevalence of diabetes was similar across geographic regions, affecting 6-9% of men. Alcohol use was highest in Australia/New Zealand and Europe, where 37% and 31% of men consumed at least 7 units per week, respectively. Smoking rates were relatively similar across regions, with 12-16% current smokers. Finally, NSAID and statin use was highest in North America (56% and 33%, respectively), relative to Europe (19% and 13%), South America (24% and 6%), and Australia/New Zealand (28% and 13%; Table 1).

### *Prevalence of acute and chronic prostate inflammation across geographic regions*

Overall, 1,070 men (15%) had acute inflammation in their baseline negative prostate biopsy. Chronic inflammation was more prevalent, affecting 5,409 men (77%); 14% had both types of inflammation and 22% had neither type of inflammation. Less than 1% had acute inflammation only, while 63% had chronic inflammation only. We observed significant differences in the prevalence of acute and chronic inflammation across geographic regions in REDUCE (Table 2). We describe results for acute inflammation in detail, noting broadly similar patterns for chronic inflammation. Overall, geographic differences observed in age-adjusted analyses remained similar in multivariable analyses. Relative to Europe, North America and Australia/New Zealand had higher prevalence of acute inflammation while South America had lower prevalence. We observed similar, albeit slightly attenuated, results for chronic inflammation, with the exception of South America where the prevalence of chronic inflammation was higher than Europe. Results were similar when men with acute inflammation were omitted from analyses of chronic inflammation, and *vice versa*, although estimates for acute inflammation in the absence of chronic inflammation were imprecise due to small numbers (Supplementary Table 1). We also observed differences in the prevalence of prostate inflammation within North American and European regions, although these were not as pronounced as differences between these regions. Relative to the US, the prevalence of acute inflammation was higher in Canada; this difference was similar in magnitude and direction for chronic inflammation, though not statistically significant. Relative to Western Europe, the prevalence of acute inflammation was lower in Northern and Eastern Europe, while the prevalence of chronic inflammation was lower in Southern Europe (Table 2). Geographic differences in extent of inflammation were similar to geographic differences in presence of inflammation, with no strong suggestion of a dose-response relationship (data not shown). Geographic patterns of acute and chronic prostate

inflammation within global, North American and European regions were similar within strata defined by median baseline PSA (all p-interactions $\geq$ 0.43), smoking status (all p-interactions $\geq$ 0.07), NSAID (all p-interactions $\geq$ 0.24) and statin use (all p-interactions $>$ 0.30). The only interaction that approached statistical significance was for smoking and chronic inflammation in association with region within Europe (p-interaction=0.07). Among men who received the 2-year biopsy, geographic differences in the prevalence of inflammation at the 2-year biopsy were similar to those at baseline, albeit with attenuated differences between Europe and North America, and between Western and Eastern Europe (Supplementary Table 2).

#### *Geographic differences in prostate cancer risk*

Overall, 833 men (15%) were diagnosed with prostate cancer at the 2-year biopsy. Prior findings from REDUCE showed that acute and chronic histologic inflammation in a negative baseline prostate biopsy were inversely associated with prostate cancer risk upon subsequent biopsy [11]. Herein, our distinct yet complementary analysis tested geographic differences in risk of prostate cancer diagnosis in REDUCE. As summarized in Figure 1, we found that regions with higher prevalence of inflammation had lower risk of prostate cancer, and *vice versa*. Specifically, North Americans and Australian/New Zealanders had higher prevalence of inflammation (Table 2) but lower prostate cancer risk than Europeans (OR 0.43; 95% CI 0.23-0.91; Table 3). Within Europe, Northern and Eastern regions had lower prevalence of prostate inflammation (Table 2) but higher prostate cancer risk than Western Europe (OR 1.29; 95% CI 1.04-1.61 and OR 1.78; 95% CI 1.32-2.40, respectively). There were no differences in prostate cancer risk between Southern and Western Europeans, or between men from Canada and the US (Table 3). Geographic differences in prostate cancer risk were similar in placebo and dutasteride arms (data not shown).

Geographic differences in prostate cancer risk within global, North American and European regions were similar within strata defined by family history of prostate cancer (all p-interactions  $\geq 0.43$ ), obesity status (all p-interactions  $\geq 0.12$ ), NSAID (all p-interactions  $\geq 0.44$ ), and statin use (all p-interactions  $\geq 0.27$ ). Adjusting our models for chronic and acute inflammation produced similar results (Supplementary Table 3).

## **Discussion**

Geographic differences in prostate cancer screening drive much of the international variation in prostate cancer incidence rates, but differences in lifestyle factors across geographic regions may also contribute [1]. Using data from 7,000 men in the multinational REDUCE trial, we report geographic differences in the prevalence of acute and chronic histologic inflammation in negative prostate biopsies. Moreover, we found that geographic variation in the prevalence of prostate inflammation in REDUCE tracked inversely with geographic differences in prostate cancer risk upon subsequent biopsy. Despite some conflicting data regarding the association between histologic prostate inflammation and prostate cancer risk, given an etiologic role for inflammation in prostate cancer [9], further study is required to determine whether prostate inflammation could contribute to international variation in prostate cancer incidence rates.

Histologic chronic and/or acute inflammation of benign prostate tissue is common, found in 60-80% of men undergoing prostate biopsy [11]. An autopsy study found a similar prevalence of histologic prostate inflammation in Asians and Caucasians [15], but other studies reported racial differences in prevalence of histologic prostate inflammation [12, 13]. Gene expression profiling revealed upregulation of inflammatory signaling pathways in resected tumors from African

Americans versus European Americans [16, 17], suggesting that the prevalence of prostate inflammation differs across distinct populations in the US. In limiting our analysis to non-Hispanic white men, this study is the first, to our knowledge, to report geographic differences in the prevalence of prostate inflammation independent of race. Causes of histologic prostate inflammation are not well understood, but may include exposure to infectious agents, urinary reflux and physical trauma [9]. We and others also reported that lifestyle factors, including smoking, serum fatty acid levels and statin use, influence both acute and chronic histologic prostate inflammation [3, 7, 8]. Lifestyle factors such as these, which influence prostate inflammation and which differ by geographic region, may contribute to geographic variation in the prevalence of histologic prostate inflammation. Given a role for prostate inflammation in benign prostate disease [15, 18] and prostate cancer [9], identifying modifiable causes of prostate inflammation could inform prevention efforts for both these prostate conditions.

Though inflammation is proposed to play an etiologic role in prostate cancer [9], epidemiologic studies examining associations between histologic prostate inflammation and prostate cancer risk have reported mixed findings. A nested case-control study within the PCPT showed that histologic inflammation of benign prostate tissue was positively associated with concomitant high-grade prostate cancer [19], and similar results were seen in another small US biopsy study [20]. A prospective analysis of PCPT participants who were subsequently enrolled in the SELECT trial also showed that the presence of prostate inflammation in benign biopsy tissue was positively associated with prostate cancer diagnosis on subsequent biopsy [21]. By contrast, results from REDUCE showed an inverse association between histologic inflammation in a negative prostate biopsy and prostate cancer risk upon subsequent PSA-independent biopsy [11]. A number of other epidemiologic studies also reported inverse associations between histologic

inflammation in negative prostate biopsies and subsequent prostate cancer risk [4, 6, 22, 23]. In patients with a negative biopsy performed due to elevated PSA, either undetected cancer or subclinical prostatitis (if histologic evidence of inflammation is present) may serve as plausible explanations for the high PSA. Thus, men with an elevated PSA caused by inflammation may be at lower risk for prostate cancer detection upon re-biopsy, versus their counterparts with elevated PSA caused by occult prostate cancer. Alternatively, immune cell infiltration may provide an immune surveillance function, thereby lowering the risk of prostate cancer. These competing mechanisms are challenging to tease apart as histologic assessment does not reveal the type of immune cell nor the activation state (e.g. CD4+ vs. CD8+ T cell). Going forward, molecular assessment of inflammation using gene expression or immunohistochemistry analyses will be required to appropriately classify this complex biologic pathway which can exert pro- and anti-tumor effects [9]. Integrating molecular and histologic assessment of inflammation could shed light on the role of inflammation in prostate cancer, and inform follow-up biopsy strategies in men with histologic inflammation in a prostate biopsy that was negative for cancer. Regardless of the reason for the inverse association between prostate inflammation and prostate cancer risk in REDUCE, our data show that geographic differences in prevalence of histologic inflammation track inversely with geographic differences in prostate cancer risk. If confirmed, our findings could guide future studies to integrate molecular data in the context of multi-national cohorts to understand mechanistic drivers of risk factor associations. These future efforts should focus on the identification of molecular biomarkers to inform prostate cancer prevention efforts and clinical decision-making.

Our study had strengths and weaknesses. First, although repeat biopsies in REDUCE were conducted independent of PSA, the baseline prostate biopsies, in which we assessed



inflammation, were largely performed due to elevated PSA. However, any selection bias introduced by the trial design would affect all REDUCE sites, and therefore should not affect our ability to detect differences in prevalence of inflammation and in prostate cancer risk across sites. Indeed, common trial eligibility criteria across REDUCE sites minimized the contribution of regional differences in clinical characteristics to regional differences in the prevalence of prostate inflammation. Second, REDUCE recruited men with an elevated PSA but had various exclusion criteria that, while increasing the homogeneity of the sample, may limit the generalizability of our results. Thus, our results from REDUCE may not be generalizable to the general population in these geographic regions. As such, rather than comparing absolute region-specific prostate cancer incidence rates, our data highlight the relationship between patterns of histologic prostate inflammation and prostate cancer risk across geographic regions. Third, we were unable to examine within-country or urban-rural differences, as country-level data was the smallest unit of geographic data available in REDUCE. Finally, we did not have access to data regarding the prostate zone sampled and were therefore unable to assess the effect of prostate zone on patterns of histologic inflammation across different geographic regions. Study strengths include the large, multinational population in REDUCE, and central pathology review of all biopsy tissues. Moreover, we adjusted our analysis for lifestyle factors that vary by region and that may affect inflammation, including smoking, obesity, NSAID and statin use, thereby reducing this potential source of confounding, though we lacked information on other lifestyle factors such as diet and exercise, as well as other factors potentially related to prostate inflammation such as sexually transmitted diseases. Finally, an additional strength was that histologic inflammation was centrally reviewed by a single pathologist in biopsies negative for prostate cancer, whereas prior studies evaluated inflammation in benign regions of the prostate

adjacent to tumor [19, 22]. Although some men may have had prostate cancer that was missed in the baseline biopsy, the REDUCE study design enables us to determine the effect of histologic prostate inflammation on prostate cancer risk while limiting the effect of inflammation as a response to the tumor.

In conclusion, a critical barrier to developing new approaches for cancer prevention is the lack of understanding of mechanisms driving tumor initiation and development [24]. Leveraging data from REDUCE, a multinational chemoprevention trial in men at high risk of prostate cancer, our findings highlight geographic differences in the prevalence of histologic inflammation in negative prostate biopsies. Moreover, we find that patterns of histologic inflammation track inversely with prostate cancer risk on subsequent biopsy in REDUCE. Characterization of premalignant prostate histology and the relationship with subsequent prostate cancer risk will improve methods for risk stratification and could inform prostate cancer prevention efforts.

**Acknowledgements:** This study was supported by the American Institute for Cancer Research (E Allott), Irish Cancer Society John Fitzpatrick Fellowship (E Allott), and NIH 1K24CA160653 (S Freedland)

## References

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, and Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin* **2015**;65:87-108.
2. Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O, *et al.* International variation in prostate cancer incidence and mortality rates. *Eur Urol* **2012**;61:1079-92.
3. Nash SH, Schenk JM, Kristal AR, Goodman PJ, Lucia MS, Parnes HL, *et al.* Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial. *Cancer Prev Res (Phila)* **2015**;8:590-6.
4. Yli-Hemminki TH, Laurila M, Auvinen A, Maattanen L, Huhtala H, Tammela TL, *et al.* Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial. *BJU Int* **2013**;112:735-41.
5. Rybicki BA, Kryvenko ON, Wang Y, Jankowski M, Trudeau S, Chitale DA, *et al.* Racial differences in the relationship between clinical prostatitis, presence of inflammation in benign prostate and subsequent risk of prostate cancer. *Prostate Cancer Prostatic Dis* **2016**;19:145-50.
6. Kryvenko ON, Jankowski M, Chitale DA, Tang D, Rundle A, Trudeau S, *et al.* Inflammation and preneoplastic lesions in benign prostate as risk factors for prostate cancer. *Mod Pathol* **2012**;25:1023-32.
7. Moreira DM, Nickel JC, Gerber L, Muller RL, Andriole GL, Castro-Santamaria R, *et al.* Smoking Is Associated with Acute and Chronic Prostatic Inflammation: Results from the REDUCE Study. *Cancer Prev Res (Phila)* **2015**;8:312-7.

8. Allott EH, Howard LE, Vidal AC, Moreira DM, Castro-Santamaria R, Andriole GL, *et al.* Statin Use, Serum Lipids, and Prostate Inflammation in Men with a Negative Prostate Biopsy: Results from the REDUCE Trial. *Cancer Prev Res (Phila)* **2017**;10:319-26.
9. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, *et al.* Inflammation in prostate carcinogenesis. *Nat Rev Cancer* **2007**;7:256-69.
10. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, *et al.* Effect of dutasteride on the risk of prostate cancer. *N Engl J Med* **2010**;362:1192-202.
11. Moreira DM, Nickel JC, Gerber L, Muller RL, Andriole GL, Castro-Santamaria R, *et al.* Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. *Cancer* **2014**;120:190-6.
12. Eastham JA, May RA, Whatley T, Crow A, Venable DD, and Sartor O. Clinical characteristics and biopsy specimen features in African-American and white men without prostate cancer. *J Natl Cancer Inst* **1998**;90:756-60.
13. Vidal AC, Chen Z, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL, *et al.* Racial differences in prostate inflammation: results from the REDUCE study. *Oncotarget* **2016**;8:71393-99.
14. Nickel JC, Freedland SJ, Castro-Santamaria R, and Moreira DM. Chronic prostate inflammation predicts symptom progression in patients with chronic prostatitis/chronic pelvic pain. *J Urol* **2017**;198:122-8.
15. Zlotta AR, Egawa S, Pushkar D, Govorov A, Kimura T, Kido M, *et al.* Prevalence of inflammation and benign prostatic hyperplasia on autopsy in Asian and Caucasian men. *Eur Urol* **2014**;66:619-22.

16. Wallace TA, Prueitt RL, Yi M, Howe TM, Gillespie JW, Yfantis HG, *et al.* Tumor immunobiological differences in prostate cancer between African-American and European-American men. *Cancer Res* **2008**;68:927-36.
17. Powell IJ, Dyson G, Land S, Ruterbusch J, Bock CH, Lenk S, *et al.* Genes associated with prostate cancer are differentially expressed in African American and European American men. *Cancer Epidemiol Biomarkers Prev* **2013**;22:891-7.
18. Nickel JC, Roehrborn CG, Castro-Santamaria R, Freedland SJ, and Moreira DM. Chronic Prostate Inflammation is Associated with Severity and Progression of Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms and Risk of Acute Urinary Retention. *J Urol* **2016**;196:1493-1498.
19. Gurel B, Lucia MS, Thompson IM, Jr., Goodman PJ, Tangen CM, Kristal AR, *et al.* Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. *Cancer Epidemiol Biomarkers Prev* **2014**;23:847-56.
20. MacLennan GT, Eisenberg R, Fleshman RL, Taylor JM, Fu P, Resnick MI, *et al.* The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. *J Urol* **2006**;176:1012-6.
21. Platz EA, Kulac I, Barber JR, Drake CG, Joshu CE, Nelson WG, *et al.* A prospective study of chronic inflammation in benign prostate tissue and risk of prostate cancer: Linked PCPT and SELECT cohorts. *Cancer Epidemiol Biomarkers Prev* **2017**;26:1549-57.

22. Karakiewicz PI, Benayoun S, Begin LR, Duclos A, Valiquette L, McCormack M, *et al.* Chronic inflammation is negatively associated with prostate cancer and high-grade prostatic intraepithelial neoplasia on needle biopsy. *Int J Clin Pract* **2007**;61:425-30.
23. Terakawa T, Miyake H, Kanomata N, Kumano M, Takenaka A, and Fujisawao M. Inverse association between histologic inflammation in needle biopsy specimens and prostate cancer in men with serum PSA of 10-50 ng/mL. *Urology* **2008**;72:1194-7.
24. Campbell JD, Mazzilli SA, Reid ME, Dhillon SS, Platero S, Beane J, *et al.* The Case for a Pre-Cancer Genome Atlas (PCGA). *Cancer Prev Res (Phila)* **2016**;9:119-24.

**Table 1:** Baseline demographic and prostate characteristics of REDUCE participants by geographic region

	Geographic region			
	Europe	North America	South America	Australia/New Zealand
<b>Participants, n</b>	4,644	1,746	466	144
<b>Age, mean (SD)</b>	63.3 (5.9)	61.5 (6.3)	62.9 (6.1)	62.0 (6.2)
<b>Prostate volume, median (IQR)</b>	32.6 (42.9-55.8)	33.8 (43.6-56.2)	35.5 (49.2-62.0)	34.6 (46.9-55.0)
<b>PSA (ng/ml), median (IQR)</b>	5.9 (4.6-7.5)	5.1 (4.0-6.6)	5.7 (4.3-7.2)	6.0 (4.8-7.4)
<b>DRE findings, n (%)</b>				
Normal/enlarged	4,548 (98)	1,610 (92)	461 (99)	135 (94)
Abnormal	96 (2)	136 (8)	5 (1)	9 (6)
<b>Family history of prostate cancer, n (%)</b>				
No	4,200 (90)	1,348 (77)	416 (89)	123 (85)
Yes	444 (10)	398 (23)	50 (11)	21 (15)
<b>Body mass index (BMI), n (%)</b>				
Normal	1,321 (28)	334 (19)	128 (27)	43 (30)
Overweight	2,507 (54)	928 (53)	247 (53)	66 (46)
Obese	816 (18)	484 (28)	91 (20)	35 (24)
<b>Diabetes, n (%)</b>				
No	4,283 (92)	1,593 (91)	431 (92)	136 (94)
Yes	361 (8)	153 (9)	35 (8)	8 (6)
<b>Alcohol intake (units/week)<sup>a</sup>, n (%)</b>				
None	974 (21)	560 (32)	146 (31)	12 (8)
≤7	2,236 (48)	872 (50)	205 (44)	79 (55)
>7	1,419 (31)	306 (18)	113 (24)	53 (37)
<b>Smoking status, n (%)</b>				
Never	2,223 (48)	716 (41)	182 (39)	64 (44)
Former	1,670 (36)	816 (47)	216 (46)	62 (43)
Current	751 (16)	214 (12)	68 (15)	18 (13)
<b>NSAID use, n (%)</b>				
No	3,760 (81)	769 (44)	355 (76)	103 (72)
Yes	884 (19)	977 (56)	111 (24)	41 (28)
<b>Statin use, n (%)</b>				
No	4,018 (87)	1,162 (67)	440 (94)	125 (87)
Yes	626 (13)	584 (33)	26 (6)	19 (13)

<sup>a</sup>alcohol intake missing for n=25 men

**Table 2:** Geographic differences in the presence of acute and chronic prostate inflammation in REDUCE

	Acute prostate inflammation				Chronic prostate inflammation			
	None	Any	OR <sup>a</sup> (95% CI)	OR <sup>b</sup> (95% CI)	None	Any	OR <sup>a</sup> (95% CI)	OR <sup>b</sup> (95% CI)
	N (%)	N (%)			N (%)	N (%)		
<b>Overall</b>	5,930 (85)	1,070 (15)			1,591 (23)	5,409 (77)		
<b>Global region</b>								
Europe	4,012 (86)	632 (14)	1 (ref)	1 (ref)	1,145 (25)	3,499 (75)	1 (ref)	1 (ref)
North America	1,372 (79)	374 (21)	1.69 (1.46-1.95)	1.77 (1.51-2.08)	324 (19)	1,422 (81)	1.50 (1.30-1.72)	1.55 (1.33-1.81)
South America	437 (94)	29 (6)	0.42 (0.29-0.62)	0.42 (0.29-0.62)	100 (21)	366 (79)	1.21 (0.96-1.52)	1.15 (0.91-1.45)
Australia/NZ	109 (76)	35 (24)	2.00 (1.36-2.96)	2.07 (1.40-3.06)	22 (15)	122 (85)	1.87 (1.18-2.96)	1.89 (1.19-3.00)
<b>North American region</b>								
United States	1,048 (80)	264 (20)	1 (ref)	1 (ref)	256 (20)	1,056 (80)	1 (ref)	1 (ref)
Canada	324 (75)	110 (25)	1.36 (1.05-1.76)	1.40 (1.07-1.83)	68 (16)	366 (84)	1.28 (0.96-1.72)	1.30 (0.96-1.77)
<b>European region</b>								
Western	1,430 (85)	261 (15)	1 (ref)	1 (ref)	390 (23)	1,301 (77)	1 (ref)	1 (ref)
Northern	1,378 (87)	208 (13)	0.81 (0.66-0.98)	0.79 (0.65-0.97)	404 (25)	1,182 (75)	0.91 (0.77-1.06)	0.90 (0.77-1.06)
Southern	710 (87)	110 (13)	0.84 (0.66-1.07)	0.84 (0.66-1.07)	226 (28)	594 (72)	0.80 (0.66-0.96)	0.77 (0.63-0.93)
Eastern	421 (90)	47 (10)	0.63 (0.45-0.87)	0.62 (0.45-0.87)	106 (27)	362 (77)	0.99 (0.78-1.27)	0.96 (0.75-1.22)

NZ=New Zealand

<sup>a</sup>adjusted for age<sup>b</sup>adjusted for age, BMI, statin use, NSAID use, smoking status, family history of prostate cancer, DRE findings, prostate volume, PSA level



**Table 3:** Geographic differences in risk of prostate cancer at 2-year repeat biopsy in REDUCE

	<b>Negative<sup>c</sup></b>	<b>Positive<sup>c</sup></b>		
	<b>N</b>	<b>N (%)</b>	<b>OR<sup>a</sup> (95% CI)</b>	<b>OR<sup>b</sup> (95% CI)</b>
<b>Overall</b>	4,820 (85)	833 (15)		
<b>Global region</b>				
Europe	3,174 (84)	597 (16)	1 (ref)	1 (ref)
North America	1,192 (87)	176 (13)	0.84 (0.70-1.01)	0.82 (0.67-1.01)
South America	344 (87)	51 (13)	0.80 (0.59-1.09)	0.88 (0.64-1.20)
Australia/New Zealand	110 (92)	9 (8)	0.46 (0.23-0.90)	0.45 (0.23-0.91)
<b>North American region</b>				
United States	873 (87)	127 (13)	1 (ref)	1 (ref)
Canada	319 (87)	49 (13)	1.02 (0.71-1.46)	1.06 (0.72-1.54)
<b>European region</b>				
Western	1,186 (86)	193 (14)	1 (ref)	1 (ref)
Northern	1,095 (83)	220 (17)	1.30 (1.05-1.61)	1.29 (1.04-1.61)
Southern	553 (85)	100 (15)	1.13 (0.87-1.47)	1.16 (0.88-1.51)
Eastern	283 (78)	81 (22)	1.66 (1.24-2.23)	1.78 (1.32-2.40)

<sup>a</sup>adjusted for age

<sup>b</sup>adjusted for age, BMI, statin use, NSAID use, smoking status, family history of prostate cancer, DRE findings, prostate volume, PSA level, treatment arm

<sup>c</sup>“Negative” and “Positive” refer to prostate cancer status based on 2-year biopsy results

## Figure legend

**Figure 1:** Summary of geographic differences in the prevalence of A. acute histologic prostate inflammation, B. chronic inflammation (grey circles) and geographic differences in prostate cancer risk at repeat biopsy (black circles). Men from geographic regions with a higher prevalence of inflammation had lower prostate cancer risk, and *vice versa*.

